Organization Overview
Historical Acquisition Tree
Alternative names
tazemetostat (Tazverik) (2020 NDA)
Carcinoma (Phase 2)
Carcinoma, Medullary (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Chordoma (Phase 2)
Hematologic Neoplasms (Phase 1)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 1)
Liver Diseases (Phase 1)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Mesothelioma (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1)
Rhabdoid Tumor (Phase 2)
Sarcoma (Phase 3)
Sarcoma, Synovial (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)